Intercept Pharmaceuticals, Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

After overcoming a financial shortfall in 2024, Inventiva is cutting staff by 50% and ceasing its preclinical research and development efforts to try to make its money last long enough to get Phase II

The role of the US Food and Drug Administration’s accelerated approval council in the approval and withdrawal of products is drawing attention as 2025 begins. A new Health and Human Services’ Office o

As the business development directors of big pharma companies flock to the annual J.P. Morgan Healthcare conference in San Francisco, important meetings will happen away from the conference ballrooms